OBJECTIVES: Deep brain stimulation (DBS) for Tourette's syndrome (TS) in various targets has been in the focus for some years. However, there are hardly any data on "psychosocial" outcome after DBS for TS. The aim of the present study therefore was to focus on the functional outcome and "psychosocial changes" in TS patients after DBS. METHODS: Six patients with treatment-refractory TS underwent GPi-DBS. The Yale Global Tic Severity Scale (YGTSS) was used to evaluate symptomatic outcome. Psychosocial changes were assessed applying the Global Assessment of Functioning Scale (GAF) and the Gilles-de-la-Tourette-Syndrome Quality-of-Life scale (GTS-QOL) with additionally documenting psychosocial changes. Follow-up ranged between 12 and 72 months. RESULTS: In all symptomatic responders (4 of 6) we found a significant functional improvement (mean GAF increasing from 53.75 (± 7.5) pre-operatively to 83.75 (± 7.5) at last follow-up) along with a positive correlation with the course of GTS-QOL (R(2) = 0.62). CONCLUSIONS: Treatment success should not only be assessed with the classic "tic-scales", but also with the GAF and GTS-QOL. Although improvement of tics seems to be positively correlated with improved functional outcome, symptomatic improvement may lead to unexpected major psychosocial changes - which both the patient and the clinicians in charge - should be prepared for.
OBJECTIVES: Deep brain stimulation (DBS) for Tourette's syndrome (TS) in various targets has been in the focus for some years. However, there are hardly any data on "psychosocial" outcome after DBS for TS. The aim of the present study therefore was to focus on the functional outcome and "psychosocial changes" in TS patients after DBS. METHODS: Six patients with treatment-refractory TS underwent GPi-DBS. The Yale Global Tic Severity Scale (YGTSS) was used to evaluate symptomatic outcome. Psychosocial changes were assessed applying the Global Assessment of Functioning Scale (GAF) and the Gilles-de-la-Tourette-Syndrome Quality-of-Life scale (GTS-QOL) with additionally documenting psychosocial changes. Follow-up ranged between 12 and 72 months. RESULTS: In all symptomatic responders (4 of 6) we found a significant functional improvement (mean GAF increasing from 53.75 (± 7.5) pre-operatively to 83.75 (± 7.5) at last follow-up) along with a positive correlation with the course of GTS-QOL (R(2) = 0.62). CONCLUSIONS: Treatment success should not only be assessed with the classic "tic-scales", but also with the GAF and GTS-QOL. Although improvement of tics seems to be positively correlated with improved functional outcome, symptomatic improvement may lead to unexpected major psychosocial changes - which both the patient and the clinicians in charge - should be prepared for.
Authors: Kara A Johnson; Gordon Duffley; Daria Nesterovich Anderson; Jill L Ostrem; Marie-Laure Welter; Juan Carlos Baldermann; Jens Kuhn; Daniel Huys; Veerle Visser-Vandewalle; Thomas Foltynie; Ludvic Zrinzo; Marwan Hariz; Albert F G Leentjens; Alon Y Mogilner; Michael H Pourfar; Leonardo Almeida; Aysegul Gunduz; Kelly D Foote; Michael S Okun; Christopher R Butson Journal: Brain Date: 2020-08-01 Impact factor: 13.501
Authors: Emma Scelzo; Jan H Mehrkens; Kai Bötzel; Paul Krack; Alexandre Mendes; Stéphan Chabardès; Mircea Polosan; Eric Seigneuret; Elena Moro; Valerie Fraix Journal: Front Neurol Date: 2015-09-01 Impact factor: 4.003
Authors: Wissam Deeb; Peter J Rossi; Mauro Porta; Veerle Visser-Vandewalle; Domenico Servello; Peter Silburn; Terry Coyne; James F Leckman; Thomas Foltynie; Marwan Hariz; Eileen M Joyce; Ludvic Zrinzo; Zinovia Kefalopoulou; Marie-Laure Welter; Carine Karachi; Luc Mallet; Jean-Luc Houeto; Joohi Shahed-Jimenez; Fan-Gang Meng; Bryan T Klassen; Alon Y Mogilner; Michael H Pourfar; Jens Kuhn; L Ackermans; Takanobu Kaido; Yasin Temel; Robert E Gross; Harrison C Walker; Andres M Lozano; Suketu M Khandhar; Benjamin L Walter; Ellen Walter; Zoltan Mari; Barbara K Changizi; Elena Moro; Juan C Baldermann; Daniel Huys; S Elizabeth Zauber; Lauren E Schrock; Jian-Guo Zhang; Wei Hu; Kelly D Foote; Kyle Rizer; Jonathan W Mink; Douglas W Woods; Aysegul Gunduz; Michael S Okun Journal: Front Neurosci Date: 2016-04-25 Impact factor: 4.677